e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
The emergence of drug-resistant tuberculosis in Europe: no cure possible?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Molecular epidemiology of M. tuberculosis drug resistance in Europe
Dick van Soolingen (Nijmegen, Netherlands)
Source:
International Congress 2015 – The emergence of drug-resistant tuberculosis in Europe: no cure possible?
Session:
The emergence of drug-resistant tuberculosis in Europe: no cure possible?
Session type:
Symposium
Number:
242
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dick van Soolingen (Nijmegen, Netherlands). Molecular epidemiology of M. tuberculosis drug resistance in Europe. International Congress 2015 – The emergence of drug-resistant tuberculosis in Europe: no cure possible?
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Molecular surveillance of multi-drug resistant tuberculosis in Europe
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Molecular epidemiology of multi drug resistance tuberculosis isolates from pulmonary tuberculosis cases from Lucknow, India
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Year: 2012
Molecular characterization of M. tuberculosis complex strains from a drug resistance survey in Albania
Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health
Year: 2013
Molecular genotyping of the clinical isolates of
mycobacterium tuberculosis
in Ukraine
Source: Eur Respir J 2006; 28: Suppl. 50, 848s
Year: 2006
Mycobacterium tuberculosis
drug resistance surveillance in Belarus
Source: Eur Respir J 2005; 26: Suppl. 49, 199s
Year: 2005
Recent transmission of drug resistant
M. tuberculosis
in Latvia
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
Genetic diversity of M. tuberculosis isolates from patients with drug-resistant TB in Japan
Source: International Congress 2018 – Current practices in and attitudes to screening for tuberculosis, and a discussion about genetic diversity
Year: 2018
Surveillance of
M. tuberculosis
drug resistance in Russia
Source: Eur Respir J 2001; 18: Suppl. 33, 513s
Year: 2001
Genotypes and drug resistance patterns of multi-drug-resistant mycobacterium tuberculosis strains in Pakistan
Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology
Year: 2015
High incidence of the Beijing strains among multi drug resistance isolates of Mycobacterium tuberculosis from extra pulmonary tuberculosis cases in northern India
Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings
Year: 2012
Molecular epidemiology of tuberculosis
Source: Eur Respir J 2002; 20: 54S-65S
Year: 2002
Molecular characterization of mycobacterium tuberculosis resistant to fluoroquinolones, distributed in Saratov region
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools
Year: 2012
Genetic markers of multi-drug and extensive drug resistant M. tuberculosis in Kyrgyz Republic
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools
Year: 2012
Molecular analysis of mutations in genes associated with multidrug-resistance in Mycobacterium tuberculosis isolates from patients with tuberculosis in Moscow region, Russia
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection
Source: Eur Respir J 2010; 36: 1242-1247
Year: 2010
Microbiology of
Mycobacterium tuberculosis
and a new diagnostic test for TB
Source: Eur Respir Mon 2012; 58: 1-13
Year: 2012
Structure of
M. tuberculosis
drug resistance in penitentiary institutions of Belarus
Source: Eur Respir J 2006; 28: Suppl. 50, 586s
Year: 2006
Secondary drug resistance tuberculosis in Iran
Source: Eur Respir J 2006; 28: Suppl. 50, 586s
Year: 2006
Standardised PCR-based molecular epidemiology of tuberculosis
Source: Eur Respir J 2008; 31: 1077-1084
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept